Diagnostics News and Research

RSS

FDA to implement Abbott's STARLIMS LIMS software

Abbott announced today that the U.S. Food and Drug Administration (FDA) will begin implementing Abbott's STARLIMS software-based laboratory information management system (LIMS) as part of the agency's initiative to enhance FDA testing laboratories.

19 Jan 2012

Quotient's ALBAcyte Reagent Red Blood Cell products receive U.S. FDA license

Quotient Biodiagnostics, Inc., a supplier of innovative and high-quality transfusion diagnostic products to hospitals, blood banks and other healthcare institutions, is pleased to announce that its range of ALBAcyte Reagent Red Blood Cell products have been licensed for sale in the USA by the Food and Drug Administration.

19 Jan 2012

New genetic signature could cause bile duct cancer

Investigators at the Massachusetts General Hospital (MGH) Cancer Center have identified a new genetic signature associated with bile duct cancer, a usually deadly tumor for which effective treatment currently is limited.

19 Jan 2012

LabCorp announces nationwide availability of Risk of Ovarian Malignancy Algorithm

Laboratory Corporation of America Holdings announced today the nationwide availability of a new FDA cleared risk stratification tool (ROMA, Risk of Ovarian Malignancy Algorithm) that combines the results for Fujirebio HE4, Abbott's ARCHITECT CA 125 II, and menopausal status into a numerical score that, along with clinical and radiological evaluation, can aid in evaluating whether a woman over the age of 18 who presents with an ovarian mass and for whom surgery is planned is at high or low likelihood of finding malignancy on surgery.

19 Jan 2012

Promega announces beta launch of Find My Gene

Promega announces the beta launch of the online gene exploration tool Find My Gene. Find My Gene integrates a number of robust functionalities to help researchers better understand their gene's function.

19 Jan 2012

New path for individually tailored cancer therapy

The Institute of Translational Oncology (TRON) together with BioNTech AG today announced the publication of a joint paper in the international journal Cancer Research that describes a new path for individually tailored cancer therapy.

18 Jan 2012

Bionime, GE enter licensing agreement to provide diabetes solutions

GE today announced it has entered into a new worldwide licensing agreement with Bionime, a global leader in biotechnology medical testing, to provide new GE-branded solutions for the diabetes market.

18 Jan 2012

Totally drug resistant Tuberculosis hits India

Reports reveal that nearly a dozen people in India are infected with a type of tuberculosis that is resistant to all antibiotics used to treat the disease and is thus named “totally drug resistant” or TDR tuberculosis.

17 Jan 2012

BJALCF receives $1 million in grants for 2012 Lung Cancer Research

Just two months shy of marking its 7-year anniversary, BJALCF announced today that it has awarded over $1 million in grants for 2012 Lung Cancer Research. BJALCF has made a promise to the Lung Cancer Community to fund only immediate results-oriented projects or programs promising to catalyze progress through early detection, genetic testing, drug discovery and patient-focused outcomes.

17 Jan 2012

Actavis, Scil Proteins sign Reteplase supply agreement

Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today that it has signed a supply agreement with Actavis, one of the world's leading generic pharmaceutical companies, for the future manufacturing of Reteplase.

17 Jan 2012

IBM's non-contact, microfluidic, silicon probe minimizes patient discomfort

IBM scientists have developed a flexible, non-contact microfluidic probe made from silicon that can aid researchers and pathologists to investigate critical tissue samples accurately for drug discovery and disease diagnostics.

13 Jan 2012

NimbleGen Sequence Capture 385K array identifies gene mutations linked with hereditary hearing loss

Hereditary hearing loss is the most common sensory disorder in humans. A German research team led by Ingo Kurth from the Institute of Human Genetics at the University Hospital Jena, Germany, used a number of different methods, including Roche's NimbleGen Custom Sequence Capture 385K array to identify the gene mutated in the disease locus of the X-chromosome of a Spanish family with hereditary hearing loss.

13 Jan 2012

Non-toxin vaccine shows promise against lethal anthrax infection

Vaccination with the anthrax capsule-a naturally occurring component of the bacterium that causes the disease-protected monkeys from lethal anthrax infection, according to U.S. Army scientists. The study, which appears in the Jan. 20th print edition of the journal VACCINE, represents the first successful use of a non-toxin vaccine to protect monkeys from the disease.

13 Jan 2012

Clinical trial to compare Aria's prenatal test and standard first-trimester screening for T21

Aria Diagnostics, a molecular diagnostics company, announced that it is initiating a blinded, multicenter clinical trial that compares its non-invasive prenatal test with the standard first-trimester screening test (serum screening and nuchal translucency ultrasound alone and in combination) to detect Trisomy 21, which is associated with Down syndrome.

13 Jan 2012

CDC, NIST develop two new SRMs for measurements of toxic environmental chemicals

The National Institute of Standards and Technology (NIST), in collaboration with the Centers for Disease Control and Prevention (CDC), has developed two new Standard Reference Materials (SRMs) for measurements of human exposure to environmental toxins.

12 Jan 2012

FDA clears Roche's Accu-Chek Nano SmartView blood glucose monitoring system

Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Accu-Chek Nano SmartView blood glucose monitoring system.

12 Jan 2012

$Merrimack commences MM-151 Phase 1 trial in refractory advanced solid tumors$

Merrimack commences MM-151 Phase 1 trial in refractory advanced solid tumors

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.

11 Jan 2012

DNA decoder – cheaper and faster

Life Technologies Corp. – a biotechnology company announced Tuesday that it has developed a machine to decode an individual's DNA in a day for just $1,000. The company said it was taking orders for the technology, which it expects to deliver in about a year. The Carlsbad, California, company said three major research institutions had already signed up for the $149,000 machine: the Baylor College of Medicine, the Yale School of Medicine and the Broad Institute of Cambridge, Massachusetts.

11 Jan 2012

Saladax increases claims in immunoassay space to 15 patents

Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that it has been issued six patents within the last 12 months, bringing the company's total to 15 issued U.S. patents, all of which contain broad claims in the immunoassay space.

11 Jan 2012

Damon Runyon Cancer Research Foundation names 18 new Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 18 new Damon Runyon Fellows at its fall Fellowship Award Committee review.

11 Jan 2012